The Ureter Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Ureter Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ureter Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued products.
GlobalData tracks 47 drugs in development for Ureter Cancer by 38 companies/universities/institutes. The top development phase for Ureter Cancer is phase ii with 28 drugs in that stage. The Ureter Cancer pipeline has 44 drugs in development by companies and three by universities/ institutes. Some of the companies in the Ureter Cancer pipeline products market are: Merck, AstraZeneca and Shenzhen Chipscreen Biosciences.
The key targets in the Ureter Cancer pipeline products market include Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, and Tubulin.
The key mechanisms of action in the Ureter Cancer pipeline product include Programmed Cell Death 1 Ligand 1 Inhibitor with seven drugs in Phase III. The Ureter Cancer pipeline products include eight routes of administration with the top ROA being Intravenous and nine key molecule types in the Ureter Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.
Ureter Cancer overview
Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra, and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy, and radiation therapy.
For a complete picture of Ureter Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
